Articles From: Abaxis, Inc. Announces USDA Approval of VetScan FeLV/FIV Feline Rapid Test to AbbVie Presents Results from Study of ABT-414 in Patients with Glioblastoma Multiforme at the 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology


UNION CITY, Calif.
Sign-up for Abaxis, Inc. Announces USDA Approval of VetScan FeLV/FIV Feline Rapid Test investment picks
2014/11/25
UNION CITY, Calif.
Sign-up for Abaxis, Inc. to Present at the 26th Annual Piper Jaffray Healthcare Conference investment picks
2015/1/6
UNION CITY, Calif.
Sign-up for Abaxis, Inc. to Present at the 33rd Annual J.P. Morgan Healthcare Conference investment picks
2014/12/5
UNION CITY, Calif.
Sign-up for Abaxis, Inc. to Present at the Bank of America Merrill Lynch 2014 Animal & Dental Summit investment picks
2014/11/14
UNION CITY, Calif.
Sign-up for Abaxis, Inc. to Present at the Canaccord Genuity Medical Technology & Diagnostic Forum investment picks
2014/11/5
UNION CITY, Calif.
Sign-up for Abaxis, Inc. to Present at the Stephens 2014 Fall Investment Conference investment picks
2014/11/12
UNION CITY, Calif.
Sign-up for Abaxis, Inc. to Present at the Stifel 2014 Healthcare Conference investment picks
Abbott Declares 364th Consecutive Quarterly Dividend ABBOTT PARK, Ill., Dec.
Sign-up for Abbott Announces Increase in Quarterly Dividend investment picks
ABBOTT PARK, Ill., Dec.
Sign-up for Abbott Completes Acquisition of Topera, Inc. investment picks
ABBOTT PARK, Ill., Dec.
Sign-up for Abbott Completes Acquisition of Veropharm investment picks
Abbott Enters Large and Growing Catheter-Based Electrophysiology Market with Next-Generation Technologies to Improve Treatment of People with Atrial Fibrillation ABBOTT PARK, Ill., Oct.
Sign-up for Abbott Expands Its Medical Device Business with Acquisition in Catheter-Based Electrophysiology Market investment picks
ABBOTT PARK, Ill., Jan.
Sign-up for Abbott Hosts Conference Call for Fourth-Quarter and Full-Year 2014 Earnings investment picks
Abbott (ABT) said Friday it is raising its quarterly dividend to 24 cents a share from 22 cents.
Sign-up for Abbott raises quarterly dividend to 24 cents a share from 22 cents investment picks
ABBOTT PARK, Ill., Nov.
Sign-up for Abbott to Present at Credit Suisse 2014 Healthcare Conference investment picks
ABBOTT PARK, Ill., Dec.
Sign-up for Abbott to Present at J.P. Morgan Healthcare Conference investment picks
- IRIDICA has the potential to change how pathogens that cause serious infections, such as sepsis and pneumonia, are detected and identified - May provide doctors with information needed to start treating those who are critically ill with appropriate therapies sooner - May help reduce the use of broad-spectrum antibiotics, a leading cause of antibiotic resistance ABBOTT PARK, Ill., Dec.
Sign-up for Abbott's Pioneering, Infectious Disease Testing Platform, IRIDICA, Now Available in Europe investment picks
Andrews & Springer LLC , a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential securities fraud and breach of fiduciary duty claims against AbbVie, Inc. (NYSE: ABBV) (“AbbVie” or the “Company”). If you currently own shares of AbbVie and want to receive additional information and protect your investments free of charge, please visit us at http://www.andrewsspringer.com/cases-investigations/ABBV or contact Craig J.
Sign-up for ABBVIE (ABBV) SHAREHOLDER ALERT – Andrews & Springer LLC Is Investigating AbbVie Inc. For Potential Securities Fraud and Breach of Fiduciary Duty investment picks
AbbVie Inc. (ABBV) on Thursday announced positive results from a late-stage trial of a treatment for endometriosis.
Sign-up for AbbVie announces positive Phase 3 trial of endometriosis treatment investment picks
- Study meets co-primary efficacy endpoints; results show treatment with elagolix reduces endometriosis-associated pain (dysmenorrhea and non-menstrual pelvic pain) compared to placebo - Results from the first of two six-month, Phase 3 studies - Full data to be presented at a future date NORTH CHICAGO, Ill.
Sign-up for AbbVie Announces Positive Top-Line Results From Phase 3 Study of Investigational Medicine Elagolix in Patients with Endometriosis investment picks
-- DUOPA is the first and only treatment providing 16 continuous hours of carbidopa and levodopa for motor fluctuations in advanced Parkinson's disease --
Sign-up for AbbVie Announces U.S. FDA Approval of DUOPA™ (carbidopa and levodopa) Enteral Suspension for the Treatment of Motor Fluctuations in Patients with Advanced Parkinson's Disease investment picks
- DUOPA is the first and only treatment providing 16 continuous hours of carbidopa and levodopa for motor fluctuations in advanced Parkinson's disease - In a clinical trial, patients treated with DUOPA experienced significantly greater improvement in "off" time than patients treated with oral carbidopa-levodopa immediate release tablets NORTH CHICAGO, Ill.
Sign-up for AbbVie Announces U.S. FDA Approval of DUOPA™ (carbidopa and levodopa) Enteral Suspension for the Treatment of Motor Fluctuations in Patients with Advanced Parkinson's Disease investment picks
The University of Illinois today announced that AbbVie (NYSE: ABBV), a global research-based biopharmaceutical company based in North Chicago, IL, has opened the AbbVie Innovation Center on campus at the University of Illinois Research Park in Urbana-Champaign.
Sign-up for AbbVie Innovation Center Opens at the University of Illinois-Urbana Research Park investment picks
- Expects Adjusted Earnings Per Share of $4.25 to $4.45 (GAAP EPS of $3.99 to $4.19); Guidance to be Further Refined as HCV Launch Progresses - Guidance Midpoint Reflects Adjusted EPS Growth of More Than 30 Percent from AbbVie's Previously Communicated 2014 Guidance Range NORTH CHICAGO, Ill.
Sign-up for AbbVie Issues Strong Outlook for 2015 investment picks
2015/1/8
By Lauren Pollock AbbVie Inc. predicted sharply higher earnings for the new year, driven by rheumatoid-arthritis drug Humira and the launch of its new hepatitis C virus treatment.
Sign-up for AbbVie Predicts Sharp Increase in Earnings investment picks
- AbbVie Presents for the First Time Results from the Venetoclax Phase 2 Program in Acute Myelogenous Leukemia - Study Evaluated Preliminary Efficacy of Venetoclax in 32 Patients with Relapsed/Refractory Acute Myelogenous Leukemia and as Frontline Therapy in Patients Unfit for Intensive Treatment NORTH CHICAGO, Ill.
Sign-up for AbbVie Presents Results from Phase 2 Study of Investigational Compound Venetoclax (ABT-199/GDC-0199) in Acute Myelogenous Leukemia at the 56th American Society of Hematology Annual Meeting investment picks
- Data include results from a Phase 1 study of ABT-414 as monotherapy and in combination with radiation and/or chemotherapy in patients with newly diagnosed and recurrent/unresectable glioblastoma multiforme - AbbVie will initiate a randomized Phase 2 trial of ABT-414 in patients with glioblastoma multiforme NORTH CHICAGO, Ill.
Sign-up for AbbVie Presents Results from Study of ABT-414 in Patients with Glioblastoma Multiforme at the 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Abaxis, Inc. Announces USDA Approval of VetScan FeLV/FIV Feline Rapid Test to AbbVie Presents Results from Study of ABT-414 in Patients with Glioblastoma Multiforme at the 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent